Theravance Biopharma (TBPH) Profit After Tax (2013 - 2026)
Theravance Biopharma (TBPH) reported Profit After Tax of -$4.9 million for Q1 2026, up 63.67% year-over-year from -$3.0 million in Q1 2025, and down 108.08% quarter-over-quarter from $61.0 million in Q4 2025.
Theravance Biopharma (TBPH) Profit After Tax (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Profit After Tax data on file, last reported at -$4.9 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$4.9 million, up 63.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $114.5 million (up 296.36% YoY), and the FY2025 annual result was $105.9 million, up 287.7% from the prior year.
- Profit After Tax slipped to -$4.9 million in Q1 2026 per TBPH's latest filing, from $61.0 million in the prior quarter.
- Over five years, Profit After Tax peaked at $61.0 million in Q4 2025 and troughed at -$41.5 million in Q1 2022.
- A 5-year average of -$5.0 million and a median of -$11.7 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2025: Profit After Tax plunged 91.0% in 2023, then jumped 493.02% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$14.3 million in 2022, then surged by 40.31% to -$8.5 million in 2023, then sank by 82.46% to -$15.5 million in 2024, then jumped by 493.02% to $61.0 million in 2025, then plunged by 108.08% to -$4.9 million in 2026.
- Business Quant data shows TBPH's Profit After Tax at -$4.9 million in Q1 2026, $61.0 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.74 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -4.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.93 Mn |
| Dec 31, 2025 | 61.02 Mn |
| Sep 30, 2025 | 3.62 Mn |
| Jun 30, 2025 | 54.84 Mn |
| Mar 31, 2025 | -13.58 Mn |
| Dec 31, 2024 | -15.53 Mn |
| Sep 30, 2024 | -12.70 Mn |
| Jun 30, 2024 | -16.53 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Dec 31, 2023 | -8.51 Mn |
| Sep 30, 2023 | -8.95 Mn |
| Jun 30, 2023 | -15.65 Mn |
| Mar 31, 2023 | -22.09 Mn |
| Dec 31, 2022 | -14.26 Mn |
| Sep 30, 2022 | -10.46 Mn |
| Jun 30, 2022 | -8.19 Mn |
| Mar 31, 2022 | -41.54 Mn |
| Dec 31, 2021 | -57.81 Mn |
| Sep 30, 2021 | -55.91 Mn |
| Jun 30, 2021 | -52.41 Mn |